European CAR T-cell Meeting
At this years 8th European CAR T-cell Meeting, taking place from 12-14 February 2026, in Palma de Mallorca, Spain, we are proud to be sharing new data and engaging with the scientific community to drive progress in the care of people living with blood cancers.
You can see the scientific programme on the congress platform by clicking on the button below.
Below is a selection of the Gilead and Kite abstracts being presented at the 8th European CAR T-cell Meeting:
Global brexucabtagene autoleucel (brexu-cel) manufacturing experience for adult patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) or mantle cell lymphoma (MCL)
iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Real-World Outcomes of Adult Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Evidence from a Multicenter Retrospective Study (MMIRROR-1)